Iptacopan

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Trial Timeline

Apr 24, 2023 → Oct 17, 2024

NCT ID

NCT05630001

About Iptacopan

Iptacopan is a phase 3 stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria. The current trial status is completed. This product is registered under clinical trial identifier NCT05630001. Target conditions include Paroxysmal Nocturnal Hemoglobinuria.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05222412	Pre-clinical	Active	—	—	C3 Glomerulopathy (C3G)
NCT06994845	Phase 3	Recruiting	Nov 27, 2025	Jun 30, 2030	Primary Immunoglobulin A Nephropathy (IgAN)
NCT06903234	Pre-clinical	Active	Mar 31, 2025	Oct 1, 2029	Hemoglobinuria, Paroxysmal
NCT06797518	Phase 2	Recruiting	Feb 21, 2025	Nov 27, 2027	Glomerulonephritis, IGA
NCT06517758	Phase 3	Recruiting	Jul 31, 2024	May 27, 2032	Generalized Myasthenia Gravis
NCT05935215	Phase 3	Recruiting	Feb 28, 2024	Jul 19, 2029	Atypical Hemolytic Uremic Syndrome
NCT05630001	Phase 3	Completed	Apr 24, 2023	Oct 17, 2024	Paroxysmal Nocturnal Hemoglobinuria
NCT04889430	Phase 3	Active	Jan 17, 2022	Aug 13, 2026	Atypical Hemolytic Uremic Syndrome
NCT05086744	Phase 2	Terminated	Dec 21, 2021	May 17, 2024	Immune Thrombocytopenia (ITP)
NCT04747613	Phase 3	Active	Jul 27, 2021	Oct 19, 2027	Paroxysmal Nocturnal Hemoglobinuria
NCT03439839	Phase 2	Completed	Apr 9, 2018	Feb 28, 2022	Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria

See all competitors

Product	Company	Stage	Hype Score
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	77
Crovalimab + Placebo	Chugai Pharmaceutical	Phase 1/2	41
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	77
Ravulizumab	AstraZeneca	Pre-clinical	23
Eculizumab	AstraZeneca	Phase 3	77
Danicopan	AstraZeneca	Phase 3	77
LNP023	Novartis	Pre-clinical	23
Iptacopan (LNP023)	Novartis	Phase 3	77
iptacopan	Novartis	Phase 2	52
LNP023	Novartis	Phase 2	52
Iptacopan	Novartis	Pre-clinical	23
LNP023 + Eculizumab + Ravulizumab	Novartis	Phase 3	77
LNP023	Novartis	Phase 3	77
LFG316 + LNP023	Novartis	Phase 2	52
Iptacopan	Novartis	Phase 3	77
Crovalimab	Roche	Phase 3	77
ABP 959 + Eculizumab	Amgen	Phase 3	76
Pegcetacoplan	Swedish Orphan Biovitrum	Pre-clinical	22
BMS-919373 + Placebo (Matching with BMS-919373)	Bristol Myers Squibb	Phase 2	51
Humanized anti-Factor Bb monoclonal antibody + Placebo	Sanofi	Phase 1	32

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved